Consistent with these findings, treatment of 4T1 tumor bearing mice with the 2G7 anti-TGF-β neutralizing antibody significantly reduced circulating VEGF levels [59](Genentech, US Patent Application 2005/0276802 A1). Here, TGFB1 is linked to neoplasm.